Press Releases

03.22.2016

Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts

03.22.2016

Pfizer Joins The Human Vaccines Project To Help Decode The Immune System

03.18.2016

Pfizer Announces Oral Tofacitinib, an Investigational JAK Inhibitor, Meets Primary and Key Secondary Endpoints in Two Pivotal Phase 3 Ulcerative Colitis Trials

03.16.2016

Pfizer to Present New Data on Investigational Tofacitinib in Inflammatory Bowel Disease at the 11th Congress of ECCO

03.15.2016

Pfizer Celebrates a Year of Achievements in 2015 Annual Review

03.11.2016

XALKORI® (crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer

03.09.2016

New Survey Reveals Many Living with Symptoms of Diabetic Nerve Pain Are Undiagnosed Despite Severe and Constant Pain

03.09.2016

Pfizer Commences $5 Billion Accelerated Share Repurchase

03.08.2016

Pfizer Announces Publication of Study Results of BeneFIX® Coagulation Factor IX (Recombinant) Once-Weekly Prophylaxis for Hemophilia B

03.08.2016

Pfizer Consumer Healthcare and frog Launch Design Collaborative

03.01.2016

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

02.24.2016

Pfizer Announces FDA Approval of XELJANZ® XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis